Boston Scientific Acquires nVision Medical

Boston Scientific has acquired nVision Medical Corporation, a privately-held company focused on women’s health. nVision developed the first and only device cleared by the USFDA to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Initial clinical research has demonstrated that the nVision device effectively collects cells which, when tested, correlate with a post-surgery definitive diagnosis of ovarian cancer.

Boston Scientific plans to conduct additional clinical research with the nVision device to further establish how the cells it collects from the fallopian tubes can be used to render a diagnosis prior to surgery and help in the decision-making process for women at increased risk for ovarian cancer. The transaction consists of an upfront cash payment of USD 150 million, and up to an additional USD 125 million in potential clinical and commercial milestones over 4 years. The acquisition is expected to be immaterial on an adjusted basis in 2018 and 2019, and accretive thereafter (dilutive on a GAAP basis through 2020 and less accretive thereafter due to amortization expense and acquisition costs).